Research programme: amyotrophic lateral sclerosis therapy - Targeted Genetics
Latest Information Update: 11 Nov 2010
At a glance
- Originator Targeted Genetics Corporation; University of Iowa
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 31 Mar 2009 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)